The Science

The Science Behind DHT and Male Pattern Baldness

DHT is the primary driver of male pattern baldness, but the mechanism is more nuanced than most people realize. Here's what the science actually says.

If you've been researching hair loss, you've almost certainly come across DHT. It's the hormone most often blamed for male pattern baldness — and for good reason. But understanding how DHT actually causes hair loss, and why it affects some follicles but not others, can help you make more informed decisions about treatment.

This article explains the science: what DHT is, how it miniaturizes hair follicles, why the pattern of loss looks the way it does, and what you can realistically do about it.

95%
of male hair loss is caused by androgenetic alopecia
The vast majority of hair loss in men is androgenetic in origin — driven by DHT and genetic sensitivity — not by stress, nutrition, or other factors, though those can worsen the condition.
American Hair Loss Association

What Is DHT?

Dihydrotestosterone (DHT) is a potent androgen derived from testosterone. It's produced when an enzyme called 5-alpha reductase (5-AR) converts testosterone to DHT in various tissues throughout the body. There are three isoforms of this enzyme: type I (primarily in sebaceous glands and liver), type II (primarily in hair follicles and prostate), and type III (skin and brain).

DHT binds to androgen receptors with approximately 5 times the potency of testosterone, making it one of the most biologically active androgens in the body. During fetal development and puberty, DHT plays an important role in the development of male sex characteristics. But in adulthood, its relationship with hair follicles becomes more complicated.

Key fact

DHT is 5× more potent than testosterone

DHT binds androgen receptors with approximately five times the affinity of testosterone itself. This makes it the dominant hormonal signal in tissues that express 5-alpha reductase — including certain hair follicles of the scalp.

How DHT Causes Hair Loss

The core mechanism of androgenetic alopecia (AGA) involves DHT binding to androgen receptors (AR) within the dermal papilla (DP) — a cluster of specialized cells at the base of the hair follicle that regulate its growth cycle.

When DHT binds to these receptors, it triggers changes in gene expression within the DP cells. This results in increased production of several signaling molecules — notably DKK1 (Dickkopf WNT Signaling Pathway Inhibitor 1) and TGF-β — that suppress hair follicle growth and shorten the anagen (active growth) phase. Over successive hair cycles, anagen gets shorter and shorter, while the telogen (resting) phase lengthens.

The result is the process known as follicular miniaturization.

The Miniaturization Process

Miniaturization doesn't happen overnight — it unfolds across many hair cycles, which is why early intervention is so important. Here is how the process typically progresses:

  1. Normal follicle: Produces a full-diameter, pigmented terminal hair. The anagen phase lasts 2–7 years.
  2. Early miniaturization: DHT shortens the anagen phase. Each cycle produces hair that is slightly thinner and shorter than before.
  3. Progressive miniaturization: Over many cycles, the hair becomes increasingly fine, lightly pigmented, and shorter — transitioning from thick terminal hairs to thin, short vellus-like hairs.
  4. Advanced miniaturization: The follicle produces very short, almost invisible hairs. The anagen phase may last only weeks.
  5. Follicle loss: In the final stages, the follicle may become entirely inactive. At this point, medical treatment cannot restore growth — only surgery can address the deficit.
Why early treatment matters

Miniaturization is partially reversible — but only early on

Treatments like finasteride and minoxidil can halt miniaturization and partially reverse it in follicles that are still active, even if significantly reduced. Once a follicle is permanently dormant, medical treatment cannot restore it. The earlier you intervene, the more you can preserve.

Why the Loss Follows a Pattern

Male pattern baldness isn't random — it follows the characteristic Norwood-Hamilton scale, with loss concentrated at the hairline, temples, and crown while the sides and back of the head remain largely unaffected. The reason for this comes down to the genetic programming of individual follicles.

Follicles on the frontal scalp, temples, and crown express significantly higher levels of androgen receptors (AR) and 5-alpha reductase type II compared to follicles in the occipital (back and sides) region. These front-of-scalp follicles are genetically predisposed to respond to DHT by entering miniaturization.

The follicles at the back and sides of the head are relatively DHT-insensitive — they largely ignore the hormonal signal. This property is the biological basis for hair transplantation: donor follicles harvested from the occipital region retain their DHT insensitivity even when transplanted to the balding areas of the scalp. This is called donor dominance.

The Genetics of DHT Sensitivity

The popular belief that baldness is inherited exclusively through the maternal line is a simplification. It's true that the androgen receptor (AR) gene is located on the X chromosome — and since men inherit their X from their mother, the maternal grandfather's hair is one useful indicator. But the genetics of AGA is highly polygenic.

Large-scale genome-wide association studies (GWAS) have identified hundreds of genetic loci associated with androgenetic alopecia — one 2017 study published in PLOS Genetics identified over 287 independent genetic signals. These variants affect not just androgen receptor sensitivity, but also hair follicle cycling, growth factor signaling, and scalp biology.

This complexity means you can't reliably predict your hair loss risk based on a single family member. Some men with heavily balding fathers retain their hair; others with no family history begin losing it in their early twenties.

What Can You Do About DHT-Driven Hair Loss?

Given that DHT is the primary driver of male pattern hair loss, the most effective medical interventions target the DHT pathway directly:

Important

Blocking DHT doesn't regrow destroyed follicles

5-AR inhibitors like finasteride and dutasteride work by halting and partially reversing the miniaturization process in active follicles. They cannot restore follicles that have already been permanently lost. If significant baldness has already occurred, hair transplant surgery may be necessary alongside medical treatment.

Key Takeaways

Frequently Asked Questions

Does high testosterone cause hair loss?

Not exactly. Total testosterone levels don't directly predict hair loss. It's the conversion of testosterone to DHT by 5-alpha reductase, and the sensitivity of your follicles to DHT, that determines your risk. Men with low testosterone can still lose hair if their follicles are DHT-sensitive.

Will lowering DHT affect my testosterone levels?

5-AR inhibitors like finasteride do not significantly reduce testosterone levels. Because conversion to DHT is blocked, testosterone levels may actually increase slightly. This does not typically produce noticeable clinical effects.

Can DHT-related hair loss affect women?

Yes, though the mechanism is somewhat different. Women have lower androgen levels overall, but some women's follicles are still sensitive enough to DHT to produce androgenetic alopecia — appearing as diffuse thinning along the part line rather than a receding hairline.

Is there a blood test to measure DHT?

Yes, serum DHT can be measured with a blood test. However, because the sensitivity of individual follicles matters more than absolute DHT levels, a normal serum DHT level does not rule out DHT-driven hair loss.

References & Citations
  1. Kaufman KD. Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin. 1996;14(4):697–711.
  2. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359–1365.
  3. Hagenaars SP, Hill WD, Harris SE, et al. Genetic prediction of male pattern baldness. PLOS Genetics. 2017;13(2):e1006561.
  4. Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8–9):981–990.
  5. Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314–328.
  6. Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001;7(7):293–301.
  7. American Hair Loss Association. Hair Loss Statistics. americanhairloss.orghttps://www.americanhairloss.org